Amyloid PET in Clinical Practice: Its Place in the Multidimensional Space of Alzheimer's Disease

Overview

Journal Neuroimage Clin

Publisher Elsevier

Specialties Neurology
Radiology

Date 2013 Nov 2

PMID 24179802

Citations 44

Authors

Rik Vandenberghe

Katarzyna Adamczuk

Patrick Dupont

Koen Van Laere

Gael Chetelat

Affiliations

Soon will be listed here.

Abstract

Amyloid imaging is currently introduced to the market for clinical use. We will review the evidence demonstrating that the different amyloid PET ligands that are currently available are valid biomarkers for Alzheimer-related β amyloidosis. Based on recent findings from cross-sectional and longitudinal imaging studies using different modalities, we will incorporate amyloid imaging into a multidimensional model of Alzheimer's disease. Aside from the critical role in improving clinical trial design for amyloid-lowering drugs, we will also propose a tentative algorithm for when it may be useful in a memory clinic environment. Gaps in our evidence-based knowledge of the added value of amyloid imaging in a clinical context will be identified and will need to be addressed by dedicated studies of clinical utility.

Citing Articles

New objective simple evaluation methods of amyloid PET/CT using whole-brain histogram and Top20%-Map.

Okuyama C, Higashi T, Ishizu K, Oishi N, Kusano K, Ito M Ann Nucl Med. 2024; 38(9):763-773.

PMID: 38907835 PMC: 11339116. DOI: 10.1007/s12149-024-01956-y.

Generation of Conventional F-FDG PET Images from F-Florbetaben PET Images Using Generative Adversarial Network: A Preliminary Study Using ADNI Dataset.

Choi H, Seo M, Kim A, Park S Medicina (Kaunas). 2023; 59(7).

PMID: 37512092 PMC: 10385186. DOI: 10.3390/medicina59071281.

Neuroimaging in Alzheimer's Disease for Early Diagnosis: A Comprehensive Review.

Aramadaka S, Mannam R, Sankara Narayanan R, Bansal A, Yanamaladoddi V, Sarvepalli S Cureus. 2023; 15(5):e38544.

PMID: 37273363 PMC: 10239271. DOI: 10.7759/cureus.38544.

Magnetic resonance evidence of increased iron content in subcortical brain regions in asymptomatic Alzheimer's disease.

Lin Q, Shahid S, Hone-Blanchet A, Huang S, Wu J, Bisht A Hum Brain Mapp. 2023; 44(8):3072-3083.

PMID: 36929676 PMC: 10171513. DOI: 10.1002/hbm.26263.

An Organometallic Gold(III) Reagent for F Labeling of Unprotected Peptides and Sugars in Aqueous Media.

McDaniel J, Stauber J, Doud E, Spokoyny A, Murphy J Org Lett. 2022; 24(28):5132-5136.

PMID: 35802398 PMC: 9573800. DOI: 10.1021/acs.orglett.2c01965.

References

Kadir A, Nordberg A . Target-specific PET probes for neurodegenerative disorders related to dementia. J Nucl Med. 2010; 51(9):1418-30. DOI: 10.2967/jnumed.110.077164. View

Nelissen N, Vandenbulcke M, Fannes K, Verbruggen A, Peeters R, Dupont P . Abeta amyloid deposition in the language system and how the brain responds. Brain. 2007; 130(Pt 8):2055-69. DOI: 10.1093/brain/awm133. View

Rowe C, Ackerman U, Browne W, Mulligan R, Pike K, OKeefe G . Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008; 7(2):129-35. DOI: 10.1016/S1474-4422(08)70001-2. View

von Gunten A, Bouras C, Kovari E, Giannakopoulos P, Hof P . Neural substrates of cognitive and behavioral deficits in atypical Alzheimer's disease. Brain Res Rev. 2006; 51(2):176-211. DOI: 10.1016/j.brainresrev.2005.11.003. View

Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R . Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. DOI: 10.1002/ana.410300410. View

Bancher C, Braak H, Fischer P, Jellinger K . Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett. 1993; 162(1-2):179-82. DOI: 10.1016/0304-3940(93)90590-h. View

Guillozet A, Weintraub S, Mash D, Marsel Mesulam M . Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003; 60(5):729-36. DOI: 10.1001/archneur.60.5.729. View

Clark C, Pontecorvo M, Beach T, Bedell B, Coleman R, Doraiswamy P . Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012; 11(8):669-78. DOI: 10.1016/S1474-4422(12)70142-4. View

Hyman B, Trojanowski J . Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997; 56(10):1095-7. DOI: 10.1097/00005072-199710000-00002. View

10.

Johnson K, Gregas M, Becker J, Kinnecom C, Salat D, Moran E . Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007; 62(3):229-34. DOI: 10.1002/ana.21164. View

11.

Rabinovici G, Jagust W, Furst A, Ogar J, Racine C, Mormino E . Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008; 64(4):388-401. PMC: 2648510. DOI: 10.1002/ana.21451. View

12.

Giannakopoulos P, Herrmann F, Bussiere T, Bouras C, Kovari E, Perl D . Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003; 60(9):1495-500. DOI: 10.1212/01.wnl.0000063311.58879.01. View

13.

Hof P, Vogt B, Bouras C, Morrison J . Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res. 1998; 37(24):3609-25. DOI: 10.1016/S0042-6989(96)00240-4. View

14.

Rosen R, Ciliax B, Wingo T, Gearing M, Dooyema J, Lah J . Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol. 2009; 119(2):221-33. PMC: 3045810. DOI: 10.1007/s00401-009-0583-3. View

15.

Devanand D, Mikhno A, Pelton G, Cuasay K, Pradhaban G, Dileep Kumar J . Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol. 2010; 23(3):185-98. PMC: 3110668. DOI: 10.1177/0891988710363715. View

16.

Joshi A, Pontecorvo M, Clark C, Carpenter A, Jennings D, Sadowsky C . Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012; 53(3):378-84. DOI: 10.2967/jnumed.111.090340. View

17.

Wolk D, Price J, Saxton J, Snitz B, James J, Lopez O . Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009; 65(5):557-68. PMC: 2828870. DOI: 10.1002/ana.21598. View

18.

Sleegers K, Lambert J, Bertram L, Cruts M, Amouyel P, Van Broeckhoven C . The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet. 2010; 26(2):84-93. DOI: 10.1016/j.tig.2009.12.004. View

19.

Mosconi L, Tsui W, Herholz K, Pupi A, Drzezga A, Lucignani G . Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008; 49(3):390-8. PMC: 3703818. DOI: 10.2967/jnumed.107.045385. View

20.

Bartlett J, Frost C, Mattsson N, Skillback T, Blennow K, Zetterberg H . Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. Biomark Med. 2012; 6(4):391-400. DOI: 10.2217/bmm.12.49. View